ALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individuals
The Company believes implementation of a
OLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash runway guidance remains
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative
120th participant has been enrolled in ALSTARS trial achieving target enrollment
Additional eligible participants already in active screening will be allowed to enroll
Topline data from 24-week double-blind
Based on current screening and enrollment rates, topline data anticipated in early Q2 2027
Additional participants continue to roll over into the active extension arm of the trial
COYA 302 has received FDA Fast
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
Virtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT
Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and
Patients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302
Coya
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful
Howard Berman, Ph.D., the Company's Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024.
Mark H. Pavao, a senior
Additions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials
ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company
